SEC Comment Letter for Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE) — Mar 11, 2025
Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: March 11, 2025 · CIK: 0001444192 · Accession: 0000000000-25-002641
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285661
Letter
Re: Grace Therapeutics, Inc. Registration Statement on Form S-3 Filed March 10, 2025 File No. 333-285661 Dear Prashant Kohli:
March 11, 2025
Prashant Kohli Chief Executive Officer Grace Therapeutics, Inc. 103 Carnegie Center, Suite 300 Princeton, NJ 08540
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Steve Abrams
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 11, 2025 Prashant Kohli Chief Executive Officer Grace Therapeutics, Inc. 103 Carnegie Center, Suite 300 Princeton, NJ 08540 Re: Grace Therapeutics, Inc. Registration Statement on Form S-3 Filed March 10, 2025 File No. 333-285661 Dear Prashant Kohli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steve Abrams </TEXT> </DOCUMENT>